Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jmri.28130 | DOI Listing |
Radiology
January 2025
From the Department of Radiology, Shenzhen Nanshan People's Hospital, Shenzhen University, Taoyuan Rd No. 89, Nanshan District, Shenzhen 518000, Guangdong, China (H.H., Z.D., Y.Q.); Medical AI Laboratory and Guangdong Key Laboratory of Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, China (J.M., R.L., B.H.); Department of Medical Imaging, People's Hospital of Longhua, Shenzhen, Guangdong, China (X.P., Y.Z.); and Department of Radiology, Shenzhen People's Hospital, Shenzhen, Guangdong, China (D.Z., G.H.).
Background Multiparametric MRI, including contrast-enhanced sequences, is recommended for evaluating suspected prostate cancer, but concerns have been raised regarding potential contrast agent accumulation and toxicity. Purpose To evaluate the feasibility of generating simulated contrast-enhanced MRI from noncontrast MRI sequences using deep learning and to explore their potential value for assessing clinically significant prostate cancer using Prostate Imaging Reporting and Data System (PI-RADS) version 2.1.
View Article and Find Full Text PDFUrology
January 2025
Department of Urology, Weill Cornell Medicine, New York, NY. Electronic address:
Insights Imaging
January 2025
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Bladder cancer is the 10th most common and 13th most deadly cancer worldwide, with urothelial carcinomas being the most common type. Distinguishing between non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) is essential due to significant differences in management and prognosis. MRI may play an important diagnostic role in this setting.
View Article and Find Full Text PDFWorld J Transplant
December 2024
Department of Radiology, Faculty of Medicine, University of Concepción, Concepción 4030000, Chile.
Liver transplantation (LT) remains the treatment of choice for early-stage hepatocellular carcinoma (HCC) and offers the best long-term oncological outcomes. However, the increasing waiting list for LT has led to a significant dropout rate as patients experience tumor progression beyond the Milan criteria. Currently, locoregional therapies, such as microwave ablation (MWA), have emerged as promising bridge treatments for patients awaiting LT.
View Article and Find Full Text PDFEur Urol
February 2025
Division of Surgery and Interventional Science, University College London, London, UK; Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!